ENERGENESIS Business Summary

Energenesis Biomedical Co., Ltd. (6657.TW) operates as a clinical-stage biopharmaceutical firm leveraging its proprietary ENERGI technology platform to develop small-molecule drugs that activate adenosine monophosphate-activated protein kinase (AMPK) to restore cellular ATP levels. The company generates revenue through a hybrid model of intellectual property licensing, R&D milestone payments, and the commercial sale of specialized bio-analytical reagents and services. Its core business segments target high-unmet-need areas: chronic wound healing (notably ENERGI-F703 for Diabetic Foot Ulcers), dermatology (ENERGI-F701 for androgenetic alopecia), and rare diseases (ENERGI-F703EB for Epidermolysis Bullosa). In the competitive TWSE biotech sector, Energenesis maintains a distinct niche against peers like Oneness Biotech (4743.TW), OBI Pharma (4174.TWO), and Senhwa Biosciences (6492.TWO) by focusing on a "cell energy" metabolic pathway that facilitates tissue repair across multiple indications. The leadership is anchored by Dr. Chen Han-min, who serves as both Chairman and General Manager (CEO) as of March 2026. A co-founder and the primary architect of the ENERGI platform, Dr. Chen holds a Ph.D. in Agricultural Chemistry from National Taiwan University and previously served as a researcher at the Children's Hospital Los Angeles (USC). The executive suite is supported by Vice President Dr. Lin Jiun-tsai, an expert in IP strategy and drug development, and Vice President Chiang Ming-tsan, who manages corporate governance and financial operations. Following a significant board restructuring in May 2025, the company has integrated institutional oversight from directors such as Jin-Hua Huang of New Prismatic Investment, aligning its scientific pedigree with disciplined capital management to support its expanding international clinical trial pipeline.